

GABA_B Receptors in Neuroendocrine Regulation

Victoria A. Lux-Lantos · María S. Bianchi ·
Paolo N. Catalano · Carlos Libertun

Received: 11 December 2007 / Accepted: 18 January 2008
© Springer Science+Business Media, LLC 2008

Abstract Gamma-amino butyric acid (GABA), in addition to being a metabolic intermediate and the main inhibitory neurotransmitter in the synaptic cleft, is postulated as a neurohormone, a paracrine signaling molecule, and a trophic factor. It acts through pre- and post-synaptic receptors, named GABA_A and GABA_C (ionotropic receptors) and GABA_B (metabotropic receptor). Here we reviewed the participation of GABA_B receptors in the regulation of the hypothalamic-pituitary-gonadal axis, using physiological, biochemical, and pharmacological approaches in rats, as well as in GABA_{B1} knock-out mice, that lack functional GABA_B receptors. Our general conclusion indicates that GABA_B receptors participate in the regulation of pituitary hormone secretion acting both in the central nervous system and directly on the gland. PRL and gonadotropin axes are affected by GABA_B receptor activation, as demonstrated in the rat and also in the GABA_{B1} knock-out mouse. In addition, hypothalamic and pituitary GABA_B receptor expression is modulated by steroid hormones. GABA participation in the brain control of pituitary

secretion through GABA_B receptors depends on physiological conditions, being age and sex critical factors.

These results indicate that patients receiving GABA_B agonists/antagonists should be monitored for possible endocrine side effects.

Keywords GABA_B receptors · Adenohypophysis · Hypothalamus · Pituitary hormones · GABA_{B1} knock-out mice

Introduction

The role of Gamma-amino butyric acid (GABA) as the predominant inhibitory neurotransmitter in the brain has been fully established. GABA is synthesized in 20–30% of all central nervous system neurons and participates in at least 40% of inhibitory synaptic processing. It is indispensable for the control of various functions such as locomotor activity, learning, and circadian rhythms (Bowery and Smart 2006; Krnjevic 2004).

Gamma-amino butyric acid synthesis is catalyzed by a 65-kDa and a 67-kDa form of glutamic acid decarboxylase (GAD) and catabolized by GABA transaminase. GABA and GAD are also found in ovaries, testis, fallopian tubes, liver, pituitary, kidney, adrenal glands, and insulin-producing β -cells of the pancreas (Fonnum 1987). The precise function of GABA in some of these tissues and cell types has yet

V. A. Lux-Lantos · M. S. Bianchi · P. N. Catalano ·
C. Libertun (✉)
Laboratory of Neuroendocrinology, Instituto de Biología
y Medicina Experimental-CONICET, V. de Obligado
2490, C1428ADN Buenos Aires, Argentina
e-mail: libertun@dna.uba.ar

P. N. Catalano · C. Libertun
Universidad de Buenos Aires, Buenos Aires, Argentina

to be determined. In addition to acting as a neurotransmitter, GABA acts as a neurohormone, a paracrine signaling molecule, a metabolic intermediate, and a trophic factor (Beleboni et al. 2004; Bowery and Smart 2006; Lujan et al. 2005).

At the time the field of neuroendocrinology started to develop the importance of neurotransmitters in hormone release began to be established. The first reports, not always in agreement, indicated prolactin and LH were pituitary hormones under GABA regulation (Ondo 1974; Libertun and McCann 1976; Mioduszewsky et al. 1976). Later, different works postulated GABA as a neuroendocrine regulator, even before a clear picture of GABA receptors was elucidated (Ondo 1974; Libertun et al. 1979; Arakelian et al. 1984; Fiszer de Plazas et al. 1982, 1983).

GABA Receptors

The first of GABA receptors to be characterized was what we today know as the GABA_A receptor (Bowery and Smart 2006). This is an ionotropic receptor, involving a chloride channel, associated with fast inhibitory conductance events. It presents a pentameric structure comprising a variety of possible combinations of protein subunits (Olsen and Tobin 1990). These receptors also have sites for positive allosteric modulation for different compounds such as benzodiazepines, anesthetics, neurosteroids (Haefely et al. 1975; Bowery and Smart 2006). Various agonists and antagonists for this receptor have been described. Similar to GABA_A receptors, GABA_C receptors represent a relatively simple form of transmitter-gated chloride channels made up of a single type of protein subunit, the Rho subunit (Chebib and Johnston 1999).

Regarding the effect of GABA on neuroendocrine regulation, a variety of effects on hormone secretion were described for its action on the GABA_A receptor, acting both at the central nervous system and directly on the gland (Libertun and McCann 1976; Libertun et al. 1979; Fiszer de Plazas et al. 1983; Apud et al. 1989; Tuomisto and Mannisto 1985; McCann and Rettori 1986; Anderson and Mitchell 1986a, b; Roussel and Astier 1990; Lacau-Mengido et al. 1989; Virmani et al. 1990; Mannisto et al. 1992; Jarvinen et al. 1992; Seong et al. 1995).

In 1980 Bowery et al. first introduced the concept of a second, pharmacologically distinct GABA receptor named GABA_B (Bowery et al. 1980). GABA_B receptors are GABA and Baclofen (β (p-chlorophenyl GABA) sensitive; muscimol, bicuculline, and picrotoxin insensitive; located pre- and post-synaptically. They are metabotropic receptors, G_{i/o}-linked and therefore Pertussis Toxin (PTX) sensitive. GABA_B receptor activation induce late, slow hyperpolarization, attenuation in membrane Ca²⁺ conductance (VSCC), increase in membrane K⁺ conductance (Kir-3), inhibition of adenylyl cyclase (Bowery 1993). All these characteristics were discovered long before the molecular structure of the receptor was resolved. In addition, Baclofen was already in clinical use as a GABA-related compound for several years, for treatment of spasticity and other neurological disorders, without any knowledge of possible side effects on, for example, the endocrine system (Enna and Bowery 2004; Bowery 2006; Ulrich and Bettler 2007).

Soon after the first description of the existence of GABA_B receptors we became interested in their possible participation in the neuroendocrine control of pituitary physiology.

GABA_B Receptors in the Brain Control of Pituitary Secretion: Pharmacological Studies

Our first question was: Are GABA_B receptors involved in the regulation of pituitary secretion? We tried to answer this hypothesis by performing a series of in vivo and in vitro experiments.

Effect of Baclofen In vivo on Basal and Stimulated Prolactin Release

First we investigated whether GABA_B receptor stimulation modified PRL secretion. Baclofen did not alter basal PRL secretion but significantly decreased stress-stimulated PRL release by a variety of stressful stimuli such as ether, immobilization, swimming, or cold (D'Eramo et al. 1986), all described to induce the secretion of this hormone (Libertun et al. 1982). This effect did not depend on the endocrine status of the animal, as the response was the same in prepubertal or castrated adult males.

Similar results were also observed in prepubertal or castrated adult females. In addition, this inhibitory effect on stress-induced PRL release was dose-dependent (Fig. 1a).


Next, the effect of Baclofen was evaluated in another physiological model, i.e., when PRL release is stimulated by suckling (Arakelian and Libertun 1977; Leong et al. 1983). In this case, pre-injection with Baclofen completely abolished the expected PRL and TSH release when pups were restored to suckling dams (Lux et al. 1986). No effect was observed on LH secretion. No difference in milk content was observed, suggesting that Baclofen was not acting on oxytocin secretion (Fig. 1b). As both PRL and TSH are under TRH regulation during suckling, this neuropeptide was a possible site of action of the drug.

Interaction of Baclofen with Neurotransmitters and Neurohormones in Pituitary Secretion

Then we tried to determine which neural pathway/s were involved in GABA_B receptor-mediated inhibition of PRL release. As dopamine is the main prolactin inhibiting hormone (Neill 1980, 1988; Libertun et al. 1982), we first evaluated if increased PRL due to dopamine receptor blockage with Haloperidol or inhibition of dopamine synthesis with α methyl-p-tyrosine were affected by Baclofen administration. The drug could not modify high PRL levels due to these drugs, possibly because the loss of dopaminergic input to the pituitary generates a very strong response in terms of PRL secretion.

Among the elusive PRL releasing factors, serotonin had been described to induce PRL release by

Fig. 1 Effect of Baclofen on stress and suckling-induced prolactin secretion. (a) Dose response effect of Baclofen (BACL) (2.5, 5, and 10 mg/kg) on prolactin secretion induced by immobilization stress in male rats. Numbers inside or above columns indicate number of rats per group. * $P < 0.05$. (Published in Proc Soc Exp Biol Med 197: 337–341:1991). (b) Effect of baclofen on PRL secretion and milk yield after 25 min suckling. Numbers inside columns indicate number of animals per group. * $P < 0.05$, compared to saline controls. Published in Proc Soc Exp Biol Med 183: 358–362:1986. Both figures are reproduced with the permission of the Society for Experimental Biology and Medicine



acting at the CNS (Becu-Villalobos et al. 1984; Pan 1991). Baclofen inhibited PRL release induced by this agent, suggesting that it could be interfering with serotonergic pathways. As TRH had also been involved in PRL secretion in situations of stress or suckling (Plotsky and Neill 1982; de Greef and Visser 1981; Johnston et al. 1984), we evaluated the effect of Baclofen under TRH administration. In this case, the drug inhibited PRL secretion but not TSH secretion. As TRH is acting directly on pituitary TRH receptors, one can assume that Baclofen does have an effect directly on the gland regulating PRL but not TSH secretion (Lux-Lantos et al. 1991).

Ontogenic Effect of Baclofen on PRL Secretion

The control of pituitary hormones secretion along ontogeny depends on the progressive development of the different neuroendocrine systems involved. In addition, GABA_B receptors have been shown to be present in the brain already at early stages of development (Knott et al. 1993). We therefore decided to evaluate the effect of Baclofen on PRL release from birth to adulthood. Surprisingly, our results showed that Baclofen had a PRL-stimulating effect that increased from 4-day-old to 20-day-old animals (Rey-Roldán et al. 1997). At 28 days of life the effect of Baclofen on PRL secretion became transiently inhibitory and thereafter no action was observed on basal secretion, as demonstrated above. Another group described a similar response in 16- and 30-day-old female rats (Moguilevsky et al. 1992). This particular ontogenic pattern of Baclofen action on PRL release was sex independent, but hormone specific, as this GABA_B agonist was devoid of action on TSH secretion at any stage of development and GABA_B receptor activation was always inhibitory on LH secretion (Moguilevsky et al. 1991). GABA_B receptors have been shown to modulate neurotransmitter systems which are involved both in inhibiting PRL secretion, such as dopamine (Santiago and Westerink 1992; Vacher et al. 2006), and in stimulating PRL secretion such as serotonin (Gray and Green 1999) (Racke et al. 1987). The balance of actions on these systems together with a direct action on the pituitary (see below) may account for this distinct pattern of PRL release. Interestingly, while the effect of Baclofen on PRL release was stimulatory, the co-administration of Baclofen with TRH induced an

additive action, suggesting different mechanisms of action. When the stimulatory effect of Baclofen on PRL secretion was lost, Baclofen inhibited the TRH-induced PRL secretion.

Thus, conclusions from these *in vivo* experiments indicated that:

- GABA_B receptors are involved in the regulation of pituitary hormones secretion.
- There is a characteristic ontogenic pattern of PRL response to GABA_B receptor stimulation, being stimulatory until 20 days of age and inhibitory or devoid of effect on basal secretion thereafter.
- GABA_B receptors participate in the regulation of PRL release induced by various stressful stimuli in adult rats. This response is not altered by the hormonal status of the animal.
- GABA_B receptors also participate in the secretion of PRL and TSH induced by suckling, without altering the release of LH or oxytocin.
- Baclofen acts at the CNS inhibiting releasing factors involved in PRL and TSH secretion such as serotonin.
- Baclofen also blunts the TRH-induced PRL release, without affecting TSH secretion, probably through a direct action at the pituitary.

As these results suggested a possible site of action for Baclofen directly at the pituitary, we directed our investigations toward this aim.

Effect of Baclofen on In Vitro-Cultured Anterior Pituitary Cells

We performed anterior pituitary cell cultures from adult rats and studied the effect of Baclofen on hormone secretion. Baclofen significantly, and concentration dependently, inhibited basal PRL secretion (Lux-Lantos et al. 1992). This effect was reversed by specific antagonists (Fig. 2). In addition, Baclofen inhibited TRH-induced PRL secretion. The GABA_B agonist also inhibited GnRH-induced LH secretion without modifying basal secretion. The same was observed for FSH. No effect was observed on TSH secretion, either basal or TRH-stimulated, in agreement with previous *in vivo* results with TRH administration (Rey-Roldán et al. 1997). Baclofen also had direct effects on hormone secretion from adenohypophyseal cells of immature rats, though




Fig. 2 Phaclofen antagonizes baclofen-induced PRL secretion inhibition in monolayer cultures of adenohypophyseal dispersed cells after 2-h incubation. Results are expressed as the percentage of control values, considering the control as 100%. a: significantly different from control values, b: significantly different from baclofen values. Published in *Neuroendocrinology* 56:687–693:1992. Reproduced with the permission of S. Karger AG, Basel

somewhat different from those observed in adults (Rey-Roldán et al. 1996). These differences probably depended on the stage of development of the neuroendocrine controls of each axis. In 12-day-old female rats, when the pituitary is highly sensitive to stimulatory inputs (Becu-Villalobos et al. 1990, 1997), Baclofen significantly inhibited GnRH-induced LH and FSH release, without affecting either basal or TRH-stimulated PRL or TSH secretion.

So we demonstrated for the first time a direct action of Baclofen on pituitary secretion, suggesting the presence of GABA_B receptors at least in some pituitary cell types. Whether the effects observed were of an autocrine or paracrine nature remained to be established.

Our next aim was the study of the mechanism of action of Baclofen at the pituitary.

GABA_B Receptor Activation in Anterior Pituitary Cells. Participation of Gi/o Proteins and Intracellular Signaling

First we showed that PTX completely inhibited the effect of Baclofen on hormone secretion in pituitary cell cultures, suggesting the participation of Gi/o proteins

(Lux-Lantos et al. 2001). As central GABA_B receptors had been demonstrated to be negatively coupled to adenylyl cyclase, we then studied the effect of Baclofen on cAMP production in pituitary cells. Forskolin, a stimulator of adenylyl cyclase, induced an increase in cAMP levels. This increase was significantly inhibited by Baclofen and the action of Baclofen was reversed either by pre-incubation with PTX or by the addition of the GABA_B receptor antagonist 2-hydroxysaclofen (Fig. 3). Therefore we demonstrated that GABA_B receptors are also negatively coupled to adenylyl cyclase in pituitary cells, involving a Gi/o protein.

As GABA_B receptors had also been postulated to inhibit calcium channels through the $\beta\gamma$ subunit of the G protein, we evaluated the effect of Baclofen on intracellular calcium titers. The drug decreased basal calcium levels without affecting TRH-induced calcium increase. This effect was much weaker than under dopamine stimulation. We next tried to determine which pathways were involved in the calcium lowering effect when GABA_B receptors were activated. On the one hand, this effect was completely abolished by pre-incubation of VGCC blockers such as Nifedipine or Verapamil. On the other hand, pre-incubation with K⁺ channel blockers such as 3-ethylammonium or Barium Chloride did not impair the effect of Baclofen on intracellular calcium titers. In addition membrane depolarization with high K⁺ again did not compromise Baclofen action. These results suggested an action




Fig. 3 Effect of baclofen on forskolin-induced cAMP production in anterior pituitary cells from proestrous rats. C: control, B: baclofen 1.10⁻⁵ M, PTX: Pertussis Toxin (150 ng/ml, 20 h), 2HO-S: 2 hydroxysaclophen 1.10⁻⁴ M, F: forskolin 0.5 μM. a: significantly different from control values, b: significantly different from F, F-B-PTX, and F-B-2HO-S. n: four experiments. Published in *Neuroendocrinology* 73: 334–343:2001. Reproduced with the permission of S. Karger AG, Basel

though calcium channels, as had been suggested for GABA_B receptor activation at pre-synaptic sites, inhibiting neurotransmitter release (Lux-Lantos et al. 2001). Similar results were obtained by another laboratory working on GABA_B receptors in neurointermediate lobe melanotropes, supporting our observations (Shibuya et al. 1999; Shibuya and Douglas 1993).

Interestingly, in preliminary experiments we determined that the effect of Baclofen on intracellular calcium in pituitary cells was lost if female rats had previously been injected with estradiol; in later experiments this observation would be investigated in depth (see below).

So the conclusions from evaluating functionality and mechanism of action of GABA_B receptors in anterior pituitary cells were:

- Indirect demonstration of the presence of GABA_B receptors in anterior pituitary cells.
- Inhibition of basal and TRH-stimulated PRL secretion by GABA_B agonists in pituitary cells from adult animals. Specificity of effects, as they were reversed by specific antagonists.
- Inhibition of GnRH-stimulated LH and FSH secretion in pituitary cells from adult and infantile animals.
- No effect was observed on TSH secretion either basally or under TRH stimulation.
- Baclofen effects were abolished by pre-incubation with PTX, suggesting the participation of Gi/0 proteins in the signaling pathway.
- GABA_B receptor activation inhibits Forskolin-induced cAMP production, indicating negative coupling to adenylyl cyclase.
- GABA_B receptor activation inhibits intracellular Ca²⁺ levels. This involves closure of VGCC.
- The mechanism of action of GABA_B receptor stimulation at the pituitary is similar to the one described at the CNS in pre-synaptic sites.

GABA_B Receptor Structure: Ontogenic Expression and Regulation of Expression of GABA_B Receptors in the Hypothalamic-Pituitary Unit

After remaining elusive for some time, finally the molecular structure of GABA_B receptors was discovered. First in 1997, the group of Dr. B. Bettler cloned

a GABA_B receptor which turned out to belong to the 7-transmembrane domain (7TM) receptors coupled to G proteins (Kaupmann et al. 1997). However, when this receptor was expressed in cells it did not function as predicted. One year later the same group, as well as others, demonstrated that the receptor was a heterodimer formed by two dissimilar 7TM subunits (Kaupmann et al. 1998; White et al. 1998; Kuner et al. 1999). GABA_{B1} provides the GABA-binding domain while GABA_{B2} provides G-protein coupling (Couve et al. 2004; Bettler and Tiao 2006). Soon thereafter Bettler et al. developed antibodies against each of the subunits of the GABA_B receptor and demonstrated that the GABA_{B1} subunit exists in two main functional isoforms, GABA_{B1a} of 120 KDa and GABA_{B1b} of 100 KDa, dimerizing with the GABA_{B2} subunit of 110 KDa (Kaupmann et al. 1998). Additional splice variants of GABA_{B1} have since been identified (Isomoto et al. 1998; Pfaff et al. 1999; Schwarz et al. 2000), though their physiological importance has not been elucidated.

In view of the new knowledge on the receptor structure, we decided to study the expression of these subunits in the hypothalamic-pituitary unit, in collaboration with Dr. Bettler.

GABA and its receptors have particular ontogenic distributions in different rat brain areas. Regarding GABA_B binding sites, some authors have described their presence in rodent brain at early stages of life, peaking at regionally specific times during the first 3 weeks of life and then declining to adult levels (Turgeon and Albin 1994; Bowery 1996; Bowery et al. 2002); others have described that they either decrease or do not change along ontogeny, depending on the region of the nervous system analyzed (Malitschek et al. 1998). In some cases, changes in the relative expression of receptor splice variants have also been reported (Fritschy et al. 1994, 1999, 2004; Malitschek et al. 1998).

Ontogenic Expression of GABA_B Receptors in the Hypothalamic-Pituitary Unit

We determined the ontogenic expression of the GABA_{B1} and GABA_{B2} subunits of the GABA_BR in the hypothalamus. Western blots analysis showed that both, GABA_{B1} and GABA_{B2}, were expressed in male and female hypothalamic membranes from day

1 to adulthood (Bianchi et al. 2005). In females, both GABA_{B1a} and GABA_{B1b} were maximally expressed in newborns and decreased toward adulthood. At birth, expression of GABA_{B1a} was significantly higher than GABA_{B1b}, while at 38 days GABA_{B1b} was more abundant. In males, GABA_{B1a} and GABA_{B1b} expression was higher in young animals and decreased gradually showing adult levels between the second and third weeks of age without differences between isoforms. Comparing GABA_{B1} variants levels in hypothalamus between sexes, GABA_{B1a} was transiently and moderately more abundant in females at birth while at 38d its expression was higher in males; GABA_{B1b} showed no sex differences along development. GABA_{B2} was detected in hypothalami of females and males at all ages; maximum levels were observed at 12 days and adult levels were attained at 38 days, without sex differences.

The hypothalamic ontogenic expression of the GABA_BR shows similarities and differences with other brain regions; this pattern was similar to the one described in spinal cord (Malitschek et al. 1998; Kaupmann et al. 1998). In contrast, in cerebellum and cerebral cortex GABA_{B1}, but not GABA_{B2}, decreased with age (Malitschek et al. 1998; Kaupmann et al. 1998). In addition, it has been postulated that both GABA_{B1} variants are differentially regulated in the brain (Benke et al. 1999). In hypothalamus GABA_{B1a} was more abundant in newborns while GABA_{B1b} was higher around puberty and thereafter, as was described for cerebral cortex, but not cerebellum, spinal cord, and midbrain (Malitschek et al. 1998); this difference was more noticeable in females. These results show that GABA_{B1a}, GABA_{B1b}, and GABA_{B2} have particular hypothalamic sex specific ontogenic expression patterns, suggesting that the expression of each isoform/subunit is under independent control during development, as was postulated during embryonic life in other brain areas (Martin et al. 2004). In addition, it suggests a specific role for each GABA_BR composition in a particular location associated to a specific function.

Our novel results demonstrated the ontogenic expression of the GABA_B receptor subunits in anterior pituitaries of male and female rats. Both isoforms of the GABA_{B1} subunit decreased with age in female pituitaries. GABA_{B1a} was significantly more expressed than GABA_{B1b} in the neonatal and infantile periods, while at adulthood this difference did not quite attain

statistical significance. The GABA_{B2} subunit was hardly detectable in anterior pituitary membranes of females at all ages (Bianchi et al. 2001). In males, GABA_{B1a} also decreased along development; GABA_{B1b} and GABA_{B2} were barely detectable. When comparing expression levels of GABA_{B1a} between sexes, we observed a very significant difference at early stages of development, being this expression increased in females (Fig. 4). Binding studies with ³H-Baclofen on pituitary membranes from males and females largely confirmed the above findings.

The decrease of GABA_{B1} expression along development was similar to our observations in hypothalamus; on the other hand, in contrast to hypothalamus and many other brain regions, in the pituitary GABA_{B1a} was the most abundant isoform at all the ages studied.

The significant difference in intensity of GABA_{B1a} expression between females and males and the lack of GABA_{B1b} expression in males suggests a sexually dimorphic expression of GABA_B subunits during ontogeny in the rat pituitary. Sexual differences in pituitary function and in central nervous system structures involved in the control of the adenohypophyseal secretion have been extensively described (Becu-Villalobos and Libertun 1995; Becu-Villalobos et al. 1997) and point to the critical role of neonatal sexual steroids in these events.




Fig. 4 Integration of GABA_{B1a} receptor subunit immunoblots of female and male developing and adult rat anterior pituitary membranes. Results in arbitrary units (AU) are the mean \pm SE of 4–5 independent samples and are expressed as the relation of each subunit with regard to the syntaxin control. a: significantly different from 12 days onwards; b: significantly different from 20 days onwards. * significantly different from males at a certain age. For all cases: $P < 0.05$ or less

Influence of Perinatal Testosterone on Pituitary GABA_{B1} Subunit Expression

In rats there is a sensitive developmental period during which sexual differentiation of neural substrates proceeds irreversibly under the influence of gonadal hormones. This period starts a few days before birth and ends approximately 10 days thereafter (Gorski 2002).

As males present two testosterone peaks, one on embryonic day 18 and one on the first day of life, we hypothesized that these could be involved in the sexually dimorphic expression of GABA_{B1} subunit of the GABA_BR observed in the pituitary.

To this aim, different *in vivo* treatments were undertaken. In Fig. 5 we show the expression of both isoforms of the GABA_{B1} subunit in 8-day-old females, 8-day-old females treated neonatally with two different doses of testosterone propionate, which have been shown to effectively androgenize females, 8-day-old males, 8-day-old males castrated neonatally, in which the second testosterone androgenizing peak was abolished, 8-day-old males treated *in utero* with flutamide, an antiandrogen that abolishes the first androgenizing peak, and 8-day-old males treated with flutamide and castrated on the day of birth (elimination of both testosterone peaks). Western blots showed that females have higher levels of expression of both isoforms of the GABA_{B1} subunit than males of the same age, as demonstrated before. High-dose testosterone treatment decreased levels of expression in females to male levels, while flutamide or flutamide plus castration increased levels of expression in males to female levels. These results were confirmed by RT-PCR studies. Therefore androgens acting pre- and post-natally decrease the expression of the pituitary GABA_{B1} subunit of the GABA_B receptor (Bianchi et al. 2004) and seem to originate the sexually dimorphic expression observed. The mechanism by which this effect is produced is still under investigation.

The evidence of steroid-dependent sexual differences in GABA_BR expression is not an isolated observation, since the participation of GABA and its receptors has been proposed to play key roles in sexual differentiation of the brain and in sexually dimorphic hormone secretion patterns (Davis et al. 1996; Murray et al. 1999; Davis et al. 2000). Continuing with the hypothesis that gonadal steroids

influenced GABA_BR expression, we evaluated the effect of estradiol on this parameter.

Effect of Estradiol on GABA_B Receptor Expression in the Hypothalamus and Pituitary of Adult Female Rats

In view of the above-mentioned results, pituitary GABA_B receptor expression seemed to be under androgen regulation. Interestingly, preliminary experiments had suggested that estrogens could also participate in the regulation of GABA_B receptors expression and/or function. We had observed that the effect of Baclofen on intracellular calcium was lost in pituitary cells when females had been injected with estrogens. To confirm this hypothesis, the expression of GABA_B receptors in the hypothalamic-pituitary unit was determined in estrogenized female rats in comparison to proestrous rats. At the pituitary, the long-term (5 weeks), but not the short-term (1 week), treatment with estradiol significantly decreased the expression of both subunits of the GABA_B receptor determined by RT-PCR. At the hypothalamus the long-term treatment decreased both subunits while the short-term treatment only reduced the GABA_{B2} subunit mRNA expression. This was also confirmed at the protein levels by Western blots (Rey-Roldan et al. 2006). This decrease in receptor expression was accompanied by a decrease in receptor function, as Baclofen was unable to modify calcium levels in long-term estrogenized female pituitary cells. This lack of response is probably due to estradiol-induced downregulation of GABA_BRs, though a desensitizing effect of the steroid cannot be discarded as previous reports have demonstrated alterations in calcium homeostasis in pituitary cells from estrogen-treated animals, including a decreased response to L-type VSCC inhibitors (Gonzalez Iglesias et al. 1999), as well as uncoupling of receptors from Gi/0 proteins (Livingstone et al. 1998; Kelly and Wagner 1999), all factors involved in the GABA_BR signaling pathway.

We conclude that chronic estradiol treatment negatively regulates the expression of the GABA_BR subunits in the pituitary and the hypothalamus. This effect is coupled to a loss of Baclofen action on intracellular calcium in pituitary cells.

Conclusions from GABA_B receptor subunit expression are:




Fig. 5 GABA_{B1} receptor subunit expression in anterior hypophysis from 8-day-old animals under different treatments determined by Western Blot with specific antisera. 8F: 8-day-old control females, 8F1TP: 8-day-old females injected with 1 μ g TP on days 1–4 of life, 8F100TP: 8-day-old females treated with 100 μ g of TP on the day of birth, 8F-Flut: 8-day-old female pups from Flutamide injected mothers, 8M: 8-day-old control males, 8MC: 8-day-old males castrated on the day of birth, 8M-Flut: 8-day-old males from Flutamide injected mothers, 8MC-Flut: 8-day-old males from Flutamide injected mothers and castrated on the day of birth. Upper panel: Representative Western Blot for GABA_{B1a} and GABA_{B1b} subunit and α syntaxin expression. Ctx: cortex membranes used as positive controls. MW: molecular weight markers. Lower

panel: Data are expressed as the ratio of GABA_{B1} subunit expression to α syntaxin expression. Number of samples per group: 8F = 12, 8F1TP = 6, 8F100TP = 12, 8F-Flut = 6, 8M = 12, 8MC = 12, 8M-Flut = 6 and 8MC-Flut = 10. Results were analyzed by two-way ANOVA: interaction: ns, indicating that both splice variants follow the same pattern of expression, factor subunit: $P < 0.001$, indicating that GABA_{B1a} is always more abundant than GABA_{B1b}, factor treatment: $P < 0.001$ or less; a: different from 8F, b: different from 8F1TP, c: different from 8F-Flut, d: different from 8M-Flut, e: different from 8MC-Flut, f: different from 8F100TP, g: different from 8M, h: different from 8MC. Published in *Neuroendocrinology* 80:129–142:2004. Reproduced with the permission of S. Karger AG, Basel

- The expression of hypothalamic and anterior pituitary GABA_B receptor subunits displays a particular ontogenic pattern being, in general, levels high at birth and decreasing toward adulthood in both sexes.
- Hypothalamic and pituitary GABA_{B1} subunits present a sexually dimorphic expression, being neonatally significantly more expressed in females than in males. This difference is more marked in the pituitary.
- Perinatal testosterone seems responsible for the lower GABA_{B1} expression levels in the adenohypophysis of neonatal males.
- In the adult female long-term estradiol treatment downregulates GABA_B receptor expression in the hypothalamus and the pituitary.

- Thus, GABA_B receptor expression is modulated by gonadal steroid hormones.

Neuroendocrine Studies in GABA_{B1} Knock-Out Mice

In the last few years Dr. Bettler's group developed two strains of mice deficient in either the GABA_{B1} subunit (Schuler et al. 2001) or the GABA_{B2} subunit (Gassmann et al. 2004), both of which suffer from spontaneous seizures, hyperalgesia, hyperlocomotor activity and severe memory impairment, and, upon administration of a GABA_B agonist, absence of typical GABA_B responses such as muscle relaxation, hypothermia, and delta EEG waves. This demonstrates that

most GABA_B functions depend on heterodimerization between the GABA_{B1} and GABA_{B2} subunits. However, GABA_{B2}KO, but not GABA_{B1}KO mice, still exhibit atypical electrophysiological GABA_B responses, indicating that, *in vivo*, GABA_{B1}, but not GABA_{B2}, can be functional in the absence of the partner subunit (Gassmann et al. 2004). More recently still, knock-out mice of each of the GABA_{B1} isoforms, GABA_{B1a} and GABA_{B1b}, have been developed by the same group, pointing to specific roles for receptor subtypes (Ulrich and Bettler 2007).

In this way a new tool came into our hands to continue our studies on the participation of GABA_B receptors in endocrine function, the GABA_{B1}KO mice, lacking the expression of both isoforms of the GABA_{B1} subunit.

Our First Question Was: Do GABA_{B1} Knock-Out Mice Show Endocrine Alterations?

We first evaluated pituitary weight and pituitary hormones serum titers in both sexes and both genotypes and found no significant differences between genotypes in most hormones, such as LH, FSH, TSH, and GH, in basal conditions. The only difference observed in these hormones were sex-related, with female mice showing larger pituitaries and male mice showing higher FSH, LH, and TSH serum levels (Catalano et al. 2005).

Prolactin

PRL was the only pituitary hormone assayed which was basally altered in GABA_{B1}KO mice, exclusively in males. Females of both genotypes showed similar PRL titers, significantly higher than wild-type (WT) males. In contrast, GABA_{B1}KO males showed significantly higher PRL than WT controls, similar to female titers. As PRL was altered in GABA_{B1}KO males we investigated whether this alteration was also evidenced when PRL was stimulated by immobilization stress. This was not the case; the increase in PRL release induced by stress was similar between genotypes. In addition, immobilization stress was proposed to reduce TSH levels in rodents (Ruisseau et al. 1978; Marti et al. 1996); this effect was observed

but, again, without differences between genotypes (Catalano et al. 2005).

Estrous cyclicity and reproductive function in GABA_{B1}KO mice

Although we did not find differences in basal gonadotropin levels or in puberty parameters between genotypes, GABA through both its receptors has been related to gonadotropin regulation. We therefore evaluated cyclicity in females from both genotypes. Estrous cycles were significantly disrupted in GABA_{B1}KO females. These animals showed longer periods in estrus, with shorter periods in proestrus (Catalano et al. 2005) (Fig. 6).

The results on estrous cycles, together with the observation in our colony that GABA_{B1}KO females did not get easily pregnant prompted us study this in more detail. To this aim we put one WT and one GABA_{B1}KO female in a cage with a male of known fertility and determined the number of pregnant females of each genotype in the first 30 days of male exposure. We also evaluated number of days to first delivery and litter size. Significantly fewer GABA_{B1}KO females got pregnant in the first 30 days of male exposure and there was also an increase in the days until delivery, though not attaining statistical significance. No difference in the number of pups per litter was detected between genotypes.

However, in the above set of experiments the difference in the pregnancy index could not discriminate between a possible lack of mating behavior, length of time in getting into proestrous or pregnancy interruption. Therefore, a new group of females from both genotypes was cycled and, on the day of proestrus, they were mated with a male of known fertility; the next day, the presence of the vaginal plug, indicative of positive mating behavior, was recorded. All WT and GABA_{B1}KO females mated on proestrous. Nevertheless, a significant difference in successful pregnancies was observed between genotypes (Catalano et al. 2005). This experiment demonstrated that even though GABA_{B1}KO females display alterations in estrous cycles, mating behavior is normal once they come into proestrus, yet at some later point fertility problems arise, which remain to be determined.


Fig. 6 Representative profiles illustrating the disruption of estrous cyclicity in $GABA_{B1}^{-/-}$ mice compared to wild-type (WT) controls, $GABA_{B1}^{+/+}$ (upper panel). Days in each phase of the estrous cycle (%) in $GABA_{B1}^{+/+}$ and $GABA_{B1}^{-/-}$ mice (lower panel). % days of estrous cycle: Student's t test. * $P < 0.001$, significantly different from WT mice.

Published in

Neuroendocrinology

82:294–305:2005.

Reproduced with the permission of S. Karger AG, Basel



Post-Castration Gonadotropin Increase in Male and Female $GABA_{B1}KO$ and Wild Mice

As cyclicity and reproductive functions were altered in female $GABA_{B1}KO$ mice, we next evaluated the functionality of the gonadotropin axis in females. We determined LH and FSH in female mice in basal conditions, 7 days after ovariectomy and with the reinstatement of the estradiol negative feedback action by estradiol administration. We observed no differences between genotypes in either LH or FSH titers (Catalano et al. 2005). But as $GABA_A$ and $GABA_B$ receptors were suggested to be involved in the late increase in LH in female rodents after castration as compared to males (Gay and Midgley 1969; Luderer and Schwartz 1994; Yoo et al. 2000; Hood and Schwartz 2000), we evaluated this response in $GABA_{B1}KO$ animals. LH rose significantly already on day 1 post-castration in males and remained elevated thereafter, without differences between genotypes. The LH rise was significantly delayed in females with regards to males. In WT females LH started to increase on day 7 post-castration. In KO females a significant advance in the LH rise was observed. On day 5, when in WT serum LH was still unchanged, in $GABA_{B1}KO$

females this hormone reached 8-fold titers, suggesting that the absence of $GABA_{B1}$ receptors was involved in this advance in LH release. This effect was specific for LH as no differences in the post-castration FSH rise were observed between genotypes in either sex (Catalano et al. 2005).

Conclusions from the Evaluation of the Hypothalamic-Pituitary-Gonadal Axis in Male and Female $GABA_{B1}KO$ and WT Mice

Our main conclusions from the evaluation of the hypothalamic-pituitary-gonadal axis in male and female $GABA_{B1}KO$ mice are:

- $GABA_{B1}KO$ males are hyperprolactinemic.
- $GABA_B$ receptors are not involved in stress-induced PRL release in mice.
- $GABA_{B1}KO$ females show alterations in the gonadotropic axis including disruption of cyclicity, impaired fertility and advanced post-castration LH increase.

These results warrant further studies to determine the neuroendocrine pathways that are disturbed by the absence of $GABA_B$ receptors or if these effects are

the consequence of absence of these receptors in target organs such as the pituitary or the gonads.

General Conclusions.

- GABA_B receptors participate in GABA regulation of pituitary function both in the central nervous system and directly at the gland.
- The PRL and gonadotropin axes are affected by GABA_B receptor activation, as demonstrated by pharmacological and biochemical approaches in the rat, as well as in the GABA_{B1}KO mouse.
- Hypothalamic and pituitary GABA_B receptor expression show specific ontogenic patterns and are modulated by steroid hormones.
- GABA participation in brain control of pituitary secretion through GABA_B receptors is age and sex dependent and varies according to the physiological conditions.

These results indicate that patients receiving GABA_B agonists/antagonists should be monitored for eventual endocrine side effects.

Acknowledgments We want to thank Dr. Bernhard Bettler, Department of Biomedicine, University of Basel, Switzerland, with whom we have a fruitful collaboration, for providing us with the antiGABA_B antibodies and the GABA_{B1} knock-out animals which permitted many of the studies herein. Funds have been provided by the Consejo Nacional de Investigaciones Científicas y Técnicas (PIP 5540), the Agencia Nacional de Promoción Científica y Tecnológica (BID 1728/OC-AR. PICT 2004 5-26307) and the Universidad de Buenos Aires (M 048).

References

- Anderson R, Mitchell R (1986a) Biphasic effect of GABAA receptor agonists on prolactin secretion: evidence for two types of GABAA receptor complex on lactotroprs. *Eur J Pharmacol* 124:1–9
- Anderson R, Mitchell R (1986b) Effects of gamma-aminobutyric acid receptor agonist on the secretion of growth hormone, luteinizing hormone, adrenocorticotrophic hormone and thyroid-stimulating hormone from the rat pituitary gland in vitro. *J Endocrinol* 108:1–8
- Apud JA, Cocchi D, Locatelli V, Masotto C, Muller EE, Racagni G (1989) Biochemical and functional aspects on the control of prolactin release by the hypothalamo-pituitary GABAergic system. *Psyconeuroendocrinol* 14:3–17
- Arakelian MC, Libertun C (1977) H1 and H2 histamine receptor participation in the brain control of prolactin secretion in lactating rats. *Endocrinology* 100:890–895
- Arakelian MC, Foglia VG, Libertun C (1984) Prolactin and milk ejection during the first 20 minutes of suckling in the rat: blockade by nembutal and by amino oxyacetic acid. *Horm Metab Res* 16:154
- Becu-Villalobos D, Libertun C (1995) Development of gonadotropin-releasing hormone (GnRH) neuron regulation in the female rat. *Cell Mol Neurobiol* 15:165–176
- Becu-Villalobos D, Lux VAR, Lacau-Mengido IM, Libertun C (1984) sexual differences in the serotonergic control of prolactin and luteinizing hormone secretion in the rat. *Endocrinology* 115:84–89
- Becu-Villalobos D, Lacau-Mengido IM, Libertun C (1990) Ontogenic studies of the neural control of the adenohipophyseal hormones in the rat: gonadotropins. *Cell Mol Neurobiol* 10:473–484
- Becu-Villalobos D, Gonzalez Iglesias A, Díaz-Torga G, Hockl P, Libertun C (1997) Brain sexual differentiation and gonadotropins secretion in the rat. *Cell Mol Neurobiol* 17:699–715
- Beleboni R, Carolino R, Pizzo A, Castellan-Baldan L, Coutinho-Netto J, dos Santos W, Coimbra N (2004) Pharmacological and biochemical aspects of GABAergic neurotransmission: pathological and neuropsychobiological relationships. *Cell Mol Neurobiol* 24:707–728
- Benke D, Honer M, Michel C, Bettler B, Mohler H (1999) Gamma-aminobutyric acid type B receptor splice variant proteins GBR1a and GBR1b are both associated with GBR2 in situ and display differential regional and subcellular distribution. *J Biol Chem* 274:27323–27330
- Bettler B, Tiao JY (2006) Molecular diversity, trafficking and subcellular localization of GABA(B) receptors. *Pharmacol Ther* 110:533–543
- Bianchi MS, Rey-Roldán EB, Bettler B, Ristig D, Malitschek B, Libertun C, Lux-Lantos V (2001) Ontogenic expression of anterior pituitary GABA_B receptor subunits. *Neuropharmacol* 40:185–192
- Bianchi MS, Catalano PN, Bonaventura MM, Silveyra P, Bettler B, Libertun C, Lux-Lantos VA (2004) Effect of androgens on sexual differentiation of pituitary gamma-aminobutyric acid receptor subunit GABA(B) expression. *Neuroendocrinology* 80:129–142
- Bianchi MS, Lux-Lantos VA, Bettler B, Libertun C (2005) Expression of gamma-aminobutyric acid B receptor subunits in hypothalamus of male and female developing rats. *Brain Res Dev Brain Res* 160:124–129
- Bowery NG (1993) GABA_B receptor pharmacology. *Ann Rev Pharmacol Toxicol* 33:109–147
- Bowery NG (1996) Pharmacology of mammalian GABAB receptors. In: Enna S, Bowery NG (eds) *The GABA receptors*. Humana Press Inc., Totowa, NJ, pp 1–30
- Bowery NG (2006) GABAB receptor: a site of therapeutic benefit. *Curr Opin Pharmacol* 6:37–43
- Bowery NG, Smart TG (2006) GABA and glycine as neurotransmitters: a brief history. *Br J Pharmacol* 147(Suppl 1):S109–S119
- Bowery NG, Hill DR, Hudson A, Doble AL, Middlesmiss DN, Shaw D, Turnbull M (1980) (-) Baclofen decreases neurotransmitter release in the mammalian CNS by action at a novel GABA receptor. *Nature* 283:92–94
- Bowery NG, Bettler B, Froestl W, Gallagher JP, Raiteri M, Bonner TI, Enna SJ (2002) International union of

- pharmacology. XXXIII. Mammalian Γ -aminobutyric acid_B receptors: structure and function. *Pharmacol Rev* 54:247–264
- Catalano PN, Bonaventura MM, Silveyra P, Bettler B, Libertun C, Lux-Lantos VA (2005) GABA(B1) knockout mice reveal alterations in prolactin levels, gonadotropic axis, and reproductive function. *Neuroendocrinology* 82: 294–305
- Chebib M, Johnston GA (1999) The “ABC” of GABA receptors: a brief review. *Clin Exp Pharmacol Physiol* 26:937–940
- Couve A, Calver AR, Fairfax B, Moss SJ, Pangalos MN (2004) Unravelling the unusual signalling properties of the GABA(B) receptor. *Biochem Pharmacol* 68:1527–1536
- D’Eramo JL, Somoza GM, Kertesz E, Libertun C (1986) Baclofen, a GABA derivative, inhibits stress-induced prolactin release in the rat. *Eur J Pharmacol* 120:81–85
- Davis AM, Grattan DR, Selmanoff M, McCarthy MM (1996) Sex differences in glutamic acid decarboxylase mRNA in neonatal rat brain: implications for sexual differentiation. *Hormones and Behavior* 30:538–552
- Davis AM, Grattan DR, McCarthy MM (2000) Decreasing GAD neonatally attenuates steroid-induced sexual differentiation of the rat brain. *Behav Neurosci* 114:923–933
- de Greef WJ, Visser TJ (1981) Evidence for the involvement of hypothalamic dopamine and thyrotrophin-releasing hormone in suckling-induced release of prolactin. *J Endocrinol* 91:213–223
- Enna SJ, Bowery NG (2004) GABA(B) receptor alterations as indicators of physiological and pharmacological function. *Biochem Pharmacol* 68:1541–1548
- Fiszer de Plazas S, Becu D, Mitridate de Novara A, Libertun C (1982) GABA receptors in anterior pituitary and brain areas after median eminence lesions. *Endocrinology* 111:1974–1978
- Fiszer de Plazas S, Seilicovich A, Duvilanski BH, González NN, Rettori V (1983) Sex related differences in GABA binding sites of rat anterior pituitary and hypothalamus. *IRCS Med Sci* 11:976
- Fonnum F (1987) Biochemistry, anatomy, and pharmacology of GABA neurons. In: Meltzer HY (ed) *Psychopharmacology: the third generation of progress*. Raven Press, New York, pp 173–182
- Fritschy JM, Paysan J, Enna A, Mohler H (1994) Switch in the expression of rat GABA_A-receptor subtypes during postnatal development: an immunohistochemical study. *J Neurosci* 14:5302–5324
- Fritschy JM, Meskenaite V, Weinmann O, Honer M, Benke D, Mohler H (1999) GABA_B-receptor splice variants GB1a and GB1b in rat brain: developmental regulation, cellular distribution and extrasynaptic localization. *Eur J Neurosci* 11:761–768
- Fritschy JM, Sidler C, Parpan F, Gassmann M, Kaupmann K, Bettler B, Benke D (2004) Independent maturation of the GABA(B) receptor subunits GABA(B1) and GABA(B2) during postnatal development in rodent brain. *J Comp Neurol* 477:235–252
- Gassmann M, Shaban H, Vigot R, Sansig G, Haller C, Barbieri S, Humeau Y, Schuler V, Muller M, Kinzel B, Klebs K, Schmutz M, Froestl W, Heid J, Kelly PH, Gentry C, Jaton AL, Van der Putten PH, Mombereau C, Lecourtier L, Mosbacher J, Cryan JF, Fritschy JM, Luthi A, Kaupmann K, Bettler B (2004) Redistribution of GABA_B(1) protein and atypical GABA_B responses in GABA_B(2)-deficient mice. *J Neurosci* 24:6086–6097
- Gay VL, Midgley AR Jr (1969) Response of the adult rat to orchidectomy and ovariectomy as determined by LH radioimmunoassay. *Endocrinology* 84:1359–1364
- Gonzalez Iglesias A, Díaz-Torga G, Lux-Lantos V, Libertun C, Becu-Villalobos D (1999) Calcium influx and intracellular stores in angiotensin ii stimulation of normal and hyperplastic pituitary cells. *Am J Physiol* 277:E455–E463
- Gorski RA (2002) Hypothalamic imprinting by gonadal steroid hormones. *Adv Exp Med Biol* 511:57–70
- Gray J, Green AR (1999) GABA_B receptor-mediated inhibition of potassium-evoked release of endogenous 5-hydroxytryptamine from mouse frontal cortex. *Br J Pharmacol* 91:517–522
- Haefely W, Kulcsar A, Mohler H, Pieri L, Polc P, Schaffner R (1975) Possible involvement of GABA in the central actions of benzodiazepines. *Adv Biochem Psychopharmacol* 14:131–151
- Hood S, Schwartz NB (2000) Sex difference in serum luteinizing hormone postgonadectomy in the rat. *Endocrine* 12:35–40
- Isomoto S, Kibara M, Sakurai-Yamashita Y, Nagayama Y, Uezono Y, Yano K, Taniyama K (1998) Cloning and tissue distribution of novel splice variants of the rat GABA_B receptor. *Biochem Biophys Res Commun* 253:10–15
- Jarvinen A, Rago L, Mannisto PT (1992) Effects of central and peripheral type benzodiazepine ligands on thyrotropin and prolactin secretion. *Neuropeptides* 21:183–191
- Johnston CA, Demarest KT, Moore KE (1984) 5-hydroxytryptamine synthesis and metabolism in discrete nuclei of the rat brain during surges of prolactin associated with restraint stress or suckling. *Neuroendocrinology* 38: 117–122
- Kaupmann K, Huggel K, Heid J, Flor P, Bischoff S, Mickel S, McMaster G, Angst C, Bittiger H, Froestl W, Bettler B (1997) Expression cloning of GABA_B receptors uncovers similarity to metabotropic glutamate receptors. *Nature* 386:239–246
- Kaupmann K, Malitschek B, Schuler B, Heid J, Froestl W, Beck P, Mosbacher J, Bischoff S, Kulik A, Shigemoto R, Karschin A, Bettler B (1998) GABA_B receptor subtypes assemble into functional heteromeric complexes. *Nature* 396:683–687
- Kelly MJ, Wagner EJ (1999) Estrogen modulation of G-protein-coupled receptors. *Trends Endocrinol Metab* 10:369–374
- Knott C, Maguire JJ, Bowery NG (1993) Age-related regional sensitivity to pertussis toxin-mediated reduction in GABA_B receptor binding in rat brain. *Mol Brain Res* 18:353–357
- Krnjevic K (2004) How does a little acronym become a big transmitter? *Biochem Pharmacol* 68:1549–1555
- Kuner R, Köhr G, Grünewald S, Eisenhardt G, Bach A, Kornau H (1999) Role of heteromer formation in GABA_B receptor function. *Science* 283:74–77
- Lacau-Mengido IM, Diaz-Torga GS, Libertun C (1989) Diazepam: endocrine effects and hypothalamic binding sites in the developing male and female rat. *Life Sci* 45:567–575

- Leong DA, Frawley LS, Neill JD (1983) Neuroendocrine control of prolactin secretion. *Annu Rev Physiol* 45: 109–127
- Libertun C, McCann SM (1976) The effect of aminooxyacetic acid and other amino acids on plasma prolactin in the rat. *IRCS Med Sci* 4:374
- Libertun C, Arakelian MC, Larrea GA, Foglia VC (1979) Inhibition of prolactin secretion by GABA in female and male Rats. *Proc Soc Exp Biol Med* 161:28–31
- Libertun C, Becu D, Arakelian MC, Somoza GM, Lux VAR (1982) Neuroendocrine control of prolactin secretion. In: De Nicola AF, Blaquier J, Soto RJ (eds) *Physiopathology of hypophysial disturbances and diseases of reproduction*. Alan R. Liss, Inc., New York, pp 131–152
- Livingstone JD, Lerant A, Freeman ME (1998) Ovarian steroids modulate responsiveness to dopamine and expression of G-proteins in lactotropes. *Neuroendocrinology* 68:172–179
- Luderer U, Schwartz NB (1994) Acute changes in pulsatile LH and FSH secretion after ovariectomy in rats: treatment with oestradiol for 24 h suppresses LH, but Not FSH, for at Least 48 h. *J Reprod Fertil* 100:613–621
- Lujan R, Shigemoto R, Lopez-Bendito G (2005) Glutamate and GABA receptor signalling in the developing brain. *Neuroscience* 130:567–580
- Lux VAR, Somoza GM, Libertun C (1986) α -[4-Chlorophenyl]GABA (baclofen) inhibits prolactin and thyrotropin release by acting on the rat brain. *Proc Soc Exp Biol Med* 183:358–362
- Lux-Lantos V, Becu-Villalobos D, Bianchi M, Rey-Roldán EB, Chamson-Reig A, Pignataro O, Libertun C (2001) GABAB receptors in anterior pituitary cells. mechanism of action coupled to endocrine effects. *Neuroendocrinology* 73:334–343
- Lux-Lantos VAR, Somoza GM, Rey EB, Libertun C (1991) Further evidence for the inhibitory action of baclofen on a prolactin-releasing factor. *Proc Soc Exp Biol Med* 197:337–341
- Lux-Lantos VAR, Rey EB, Libertun C (1992) Activation of GABA B receptors in the anterior pituitary inhibits prolactin and luteinizing hormone secretion. *Neuroendocrinology* 56:687–693
- Malitschek B, Rüegg D, Heid J, Kaupmann K, Bittiger H, Froestl W, Bettler B, Kuhn R (1998) developmental changes of agonist affinity at GABA_BR1 receptor variants in the rat. *Mol Cell Neurosci* 12:56–64
- Mannisto PT, Laakso ML, Jarvinen A, Rago L (1992) Effects of central and peripheral type benzodiazepine ligands on growth hormone and gonadotropin secretion in male rats. *Pharmacol Toxicol* 71:75–80
- Marti O, Gavaldà A, Jolin T, Armario A (1996) Acute stress attenuates but does not abolish circadian rhythmicity of serum thyrotrophin and growth hormone in the rat. *Eur J Endocrinol* 135:703–708
- Martin SC, Steiger JL, Gravielle MC, Lyons HR, Russek SJ, Farb DH (2004) Differential expression of gamma-aminobutyric acid Type B receptor subunit MRNAs in the developing nervous system and receptor coupling to adenylyl cyclase in embryonic neurons. *J Comp Neurol* 473:16–29
- McCann SM, Rettori V (1986) Gamma Amino Butyric Acid (GABA) controls anterior pituitary hormone secretion. *Adv Biochem Psychopharmacol* 42:173–189
- Mioduszewsky R, Grandison L, Meites J (1976) Stimulation of prolactin release in rats by GABA. *Proc Soc Exp Biol Med* 151:44–46
- Moguilevsky JA, Carbone S, Szwarcfarb B, Rondina D (1991) Sexual maturation modifies the GABAergic control of gonadotrophin secretion in female rats. *Brain Res* 563:12–16
- Moguilevsky JA, Carbone S, Szwarcfarb B (1992) Changes in the effect of gamma-aminobutyric acid on prolactin secretion during sexual maturation in female rats. *Endocrinology* 131:458–462
- Murray HE, Rantle CM, Simonian SX, DonCarlos LL, Herbison AE, Gillies GE (1999) Sexually dimorphic ontogeny of GABAergic influences on periventricular somatostatin Neurons. *Neuroendocrinology* 70:384–391
- Neill JD (1980) Neuroendocrine regulation of Prolactin secretion. In: Martini L, Gannong W (eds) *Frontiers in neuroendocrinology*. Raven Press, New York, pp 129–155
- Neill JD (1988) Prolactin secretion and its control. In: Knobil E, Neill JD (eds) *The physiology of reproduction*. Raven Press, New York, pp 1379–1390
- Olsen RW, Tobin AJ (1990) Molecular biology of GABAA receptors. *FASEB J* 4:1469–1480
- Ondo JG (1974) Gamma-aminobutyric acid effects on pituitary gonadotropin secretion. *Science* 186:738–739
- Pan JT (1991) Neuroendocrine control of prolactin secretion: the role of the serotonergic system. *Chin J Physiol* 34:45–64
- Pfaff T, Malitschek B, Kaupmann K, Prézeau L, Pin J-P, Bettler B, Karschin A (1999) Alternative splicing generates a novel isoform of the rat metabotropic GABA_BR1 receptor. *Eur J Neurosci* 11:2874–2882
- Plotsky PM, Neill JD (1982) Interactions of dopamine and thyrotropin-releasing hormone in the regulation of prolactin release in lactating rats. *Endocrinology* 111: 168–173
- Racke K, Holzbauer M, Sharman DF, Cooper TR (1987) GABAA and GABAB receptor-mediated inhibition of release of 5-hydroxytryptamine in the intermediate lobe of the rat pituitary gland. *Neuroscience* 23:679–684
- Rey-Roldán EB, Lux-Lantos VAR, Gonzalez Iglesias A, Becu-Villalobos D, Libertun C (1996) Baclofen, a gamma-aminobutyric acid B agonist, modifies hormonal secretion in pituitary cells from infantile female rats. *Life Sci* 58:1059–1065
- Rey-Roldán EB, Lux-Lantos V, Chamson-Reig A, Libertun C (1997) In vivo interaction of baclofen, TRH and serotonin on PRL and TSH secretion in the developing and adult male and female rats. *Life Sci* 61:2283–2290
- Rey-Roldán EB, Bianchi MS, Bettler B, Becu-Villalobos D, Lux-Lantos VA, Libertun C (2006) Adenohypophysial and hypothalamic GABA B receptor subunits are down-regulated by estradiol in adult female rats. *Life Sci* 79:342–350
- Roussel JP, Astier H (1990) Involvement of dihydropyridine-sensitive calcium channels in the GABAA potentiation of TRH-induced TSH release. *Eur J Pharmacol* 190:135–145
- Ruisseau PD, Tache Y, Brazeau P, Collu R (1978) Pattern of adenohypophysial hormone changes induced by various

- stressors in female and male rats. *Neuroendocrinology* 27:257–271
- Santiago M, Westerink BH (1992) The role of GABA receptors in the control of nigrostriatal dopaminergic neurons: dual-probe microdialysis study in awake rats. *Eur J Pharmacol* 219:175–181
- Schuler V, Luscher C, Blanchet C, Klix N, Sansig G, Klebs K, Schmutz M, Heid J, Gentry C, Urban L, Fox A, Spooren W, Jatton AL, Vigouret J, Pozza M, Kelly PH, Mosbacher J, Froestl W, Kaslin E, Korn R, Bischoff S, Kaupmann K, van der Putten H, Bettler B (2001) Epilepsy, hyperalgesia, impaired memory, and loss of pre- and postsynaptic GABA(B) responses in mice lacking GABA(B(1)). *Neuron* 31:47–58
- Schwarz DA, Barry G, Eliasof SD, Petroski RE, Conlon PJ, Maki RA (2000) Characterization of Γ -aminobutyric acid receptor GABA_{B(1e)}, a GABA_{B(1)} splice variant encoding a truncated receptor. *J Biol Chem* 275:32174–32181
- Seong JY, Jarry H, Kuhnemuth S, Leonhardt S, Wuttke W, Kim K (1995) Effect of GABAergic compounds on gonadotropin-releasing hormone receptor gene expression in the rat. *Endocrinology* 136:2587–2593
- Shibuya I, Douglas WW (1993) Indications from Mn-quenching of fura-2 fluorescence in melanotrophs that dopamine and baclofen close Ca channels that are spontaneously open but not those opened by high [K⁺]_o; and that Cd preferentially blocks the latter. *Cell Calcium* 14:33–44
- Shibuya I, Harayama N, Sasaki N, Uezono Y, Tanaka K, Ueta Y, Yamashita H (1999) Distinct cellular mechanisms utilized by GABAB and dopamine D2 receptors in suppressing Ca²⁺ signalling of pituitary melanotrophs. GABAB receptors the 8th neuropharmacology conference, Miami, USA P23:109
- Tuomisto J, Mannisto P (1985) Neurotransmitter regulation of anterior pituitary hormones. *Pharmacol Rev* 37:249
- Turgeon SM, Albin RL (1994) Postnatal ontogeny of GABAB binding in the rat brain. *Neuroscience* 62:601–613
- Ulrich D, Bettler B (2007) GABA(B) receptors: synaptic functions and mechanisms of diversity. *Curr Opin Neurobiol* 17:298–303
- Vacher CM, Gassmann M, Desrayaud S, Challet E, Bradaia A, Hoyer D, Waldmeier P, Kaupmann K, Pevet P, Bettler B (2006) Hyperdopaminergia and altered locomotor activity in GABAB1-deficient mice. *J Neurochem* 97:979–991
- Virmani MA, Stojilkovic SS, Catt KJ (1990) Stimulation of luteinizing hormone release by Γ -aminobutyric acid (GABA) agonists: mediation by GABA A-type receptors and activation of chloride and voltage-sensitive calcium channels. *Endocrinology* 126:2499–2505
- White J, Wise A, Main M, Green A, Fraser N, Disney G, Barnes A, Emson P, Foord S, Marshall F (1998) Heterodimerization is required for the formation of a functional GABAB receptor. *Nature* 396:679–682
- Yoo MJ, Searles RV, He JR, Shen W, Grattan DR, Selmanoff M (2000) Castration rapidly decreases hypothalamic Γ -aminobutyric acidergic neuronal activity in both male and female rats. *Brain Res* 878:1–10